Literature DB >> 10403013

Nicotine enhancement of contextual fear conditioning.

T J Gould1, J M Wehner.   

Abstract

Nicotine has been suggested to have cognitive enhancing effects. The present study examined the effects of nicotine and the nicotinic antagonist mecamylamine on contextual fear conditioning in C57BL/6 mice. The fear conditioning task was chosen because the task examines two types of learning: contextual learning, and conditioned stimulus (CS)-unconditioned stimulus (US) learning. Multiple doses of nicotine were tested and 0.5 mg/kg nicotine, given on both training and testing days, improved contextual learning but had no effect on formation of an auditory CS-US association. No effect was found at lower doses or when nicotine was given on training day only, or testing day only. The nicotinic receptor antagonist mecamylamine (1 and 2 mg/kg) did not alter contextual fear conditioning but mecamylamine did prevent the nicotine-associated increase in contextual learning. A higher dose of nicotine (1 mg/kg, training day only) interfered with contextual conditioning when the context was paired with both the CS and US, but had no effect on the auditory CS-US association. This effect of 1 mg/kg nicotine on contextual learning disappeared when mice were trained without the CS. The present results indicate that nicotine enhancement of contextual fear conditioning is dose-dependent, but the presence of nicotine is required both during training and testing.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10403013     DOI: 10.1016/s0166-4328(98)00157-0

Source DB:  PubMed          Journal:  Behav Brain Res        ISSN: 0166-4328            Impact factor:   3.332


  85 in total

1.  Chronic fluoxetine ameliorates adolescent chronic nicotine exposure-induced long-term adult deficits in trace conditioning.

Authors:  David A Connor; Thomas J Gould
Journal:  Neuropharmacology       Date:  2017-08-02       Impact factor: 5.250

2.  The effects of galantamine on nicotine withdrawal-induced deficits in contextual fear conditioning in C57BL/6 mice.

Authors:  Derek S Wilkinson; Thomas J Gould
Journal:  Behav Brain Res       Date:  2011-04-14       Impact factor: 3.332

Review 3.  Tobacco addiction and the dysregulation of brain stress systems.

Authors:  Adrie W Bruijnzeel
Journal:  Neurosci Biobehav Rev       Date:  2012-03-03       Impact factor: 8.989

Review 4.  Mouse models for studying genetic influences on factors determining smoking cessation success in humans.

Authors:  F Scott Hall; Athina Markou; Edward D Levin; George R Uhl
Journal:  Ann N Y Acad Sci       Date:  2012-02       Impact factor: 5.691

5.  The role of nicotinic acetylcholine receptors in the medial prefrontal cortex and hippocampus in trace fear conditioning.

Authors:  J D Raybuck; T J Gould
Journal:  Neurobiol Learn Mem       Date:  2010-08-19       Impact factor: 2.877

6.  Nicotine Addiction and Psychiatric Disorders.

Authors:  Munir Gunes Kutlu; Vinay Parikh; Thomas J Gould
Journal:  Int Rev Neurobiol       Date:  2015-09-19       Impact factor: 3.230

Review 7.  Nicotinic modulation of hippocampal cell signaling and associated effects on learning and memory.

Authors:  Munir Gunes Kutlu; Thomas J Gould
Journal:  Physiol Behav       Date:  2015-12-11

8.  Nicotinic receptors in the dorsal and ventral hippocampus differentially modulate contextual fear conditioning.

Authors:  Justin W Kenney; Jonathan D Raybuck; Thomas J Gould
Journal:  Hippocampus       Date:  2012-01-23       Impact factor: 3.899

9.  Acute ethanol has biphasic effects on short- and long-term memory in both foreground and background contextual fear conditioning in C57BL/6 mice.

Authors:  Danielle Gulick; Thomas J Gould
Journal:  Alcohol Clin Exp Res       Date:  2007-09       Impact factor: 3.455

10.  Involvement of hippocampal jun-N terminal kinase pathway in the enhancement of learning and memory by nicotine.

Authors:  Justin W Kenney; Cédrick Florian; George S Portugal; Ted Abel; Thomas J Gould
Journal:  Neuropsychopharmacology       Date:  2010-01       Impact factor: 7.853

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.